VIDEO: Triplet therapy shows benefit in intermediate-risk renal cell carcinoma

ByMoshe Ornstein, MD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

SAN FRANCISCO — Healio spoke with Moshe Ornstein, MD, about the COSMIC-313 trial presented at the annual ASCO Genitourinary Cancers Symposium.

Treatment-naive patients with intermediate- or poor-risk advanced metastatic renal cell carcinoma were treated with a regimen of cabozantinib (Cabometyx, Exelixis) plus nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) or nivolumab and ipilimumab, according to the abstract.

The updated outcomes from COSMIC-313 assessed PFS, overall response rate and complete response by International mRCC Database Consortium (IMDC) risk groups.

“What we see from COSMIC-313 is that the PFS was superior in the triplet versus the doublet, as was the response rate,” Ornstein, genitourinary medical oncologist at Cleveland Clinic Taussig Cancer Institute, said. “But when you look at the subgroups, that benefit appears to be in the intermediate-risk patients and not necessarily in the poor-risk patients.”

Reference:

Powles T, et al. Abstract 605. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Ornstein reports serving as a consultant or in an advisory role for Aveo, Bristol Myers Squibb, Eisai, Exelixis, Merck and Pfizer; serving on speakers bureaus for Bristol Myers Squibb and Merck; receiving institutional research funding from Aravive, Astra-Zeneca, Astellas, Bristol Myers Squibb, Merck, Pfizer and Surface Oncology; and receiving reimbursement for travel and accommodations expenses from Bristol Myers Squibb, Eisai, Exelixis and Pfizer.

Take Homes in Renal Cell Carcinoma

Read more

VIDEO: Triplet therapy shows benefit in intermediate-risk renal cell carcinoma

Reference:

Related Content